IL‐1 receptor antagonist plus pentoxifylline and zinc for severe alcohol‐associated hepatitis
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background and Aims: Patients with severe alcohol‐associated hepatitis (AH) have high mortality. Corticosteroids improve survival only for 30 days. We targeted inflammation, cellular injury, and gut leakiness in a randomized clinical trial comparing combination therapy to corticosteroids on 180‐day survival. Approach and Results: Subjects with a clinical diagnosis of severe AH (Model for End‐Stage Liver Disease [MELD] >20, Maddrey discriminant function [MDF] >32) were randomized to receive methylprednisolone (PRED; 28 days) or a combination of anakinra (14 days) plus pentoxifylline (28 days) plus zinc (COMB; 180 days). The primary endpoint was survival at 180 days. The study was designed in 2013, initiated in October 2014, and completed in March 2018. Five hundred patients were screened to randomize 104 subjects with a clinical diagnosis of AH with a MELD score >20. Fifty‐three patients were randomized into the COMB and 50 to the PRED treatment; 1 dropped out of the study before randomization. Mean age was 45.3 ± 10.4 years; 60.6% were males, 92.3% White, and mean MELD 25.7 ± 3.9. Kaplan‐Meier survival estimate at 180 days was 67.9% in COMB and 56% in PRED (HR = 0.69; p = 0.3001). Survival curves separated by 90 days (COMB, 69.8%; PRED, 58.0%; HR = 0.69; p = 0.28). Survival at 28 days was similar between the COMB (83.4%) and PRED groups (81.2%; HR = 0.91; p = 0.85). There were no unexpected serious adverse events, and incidence of infection was comparable between groups. MELD 20–25 and MELD >26 strata showed nonsignificant treatment effects in favor of COMB. Conclusions: A combination of anakinra, pentoxifylline plus zinc provides similar survival benefits compared to corticosteroid therapy in severe AH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384
IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice
Petrasek, J., Bala, S., Csak, T., Lippai, D., Kodys, K., Menashy, V., Barrieau, M., Min, S.-Y., Kurt-Jones, E. A., & Szabo, G. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60777 · Cited by 735 · cited 1×
“[19– 21] In a preclinical model of alcohol- associated liver disease (ALD), inhibition of IL1 signaling with the IL1 receptor antagonist (IL1RA), anakinra, attenuated liver damage, prevented inflammation, and improved liver regeneration.[22,23] Given the complexity of the pathobiology of AH, the present study evaluate…”
BackgroundThe role of zinc deficiency in alcohol-induced intestinal barrier dysfunction
Zhong, W., McClain, C. J., Cave, M., Kang, Y. J., & Zhou, Z. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00350.2009 · Cited by 214
Self-citation
Cited by
Alcohol-associated liver disease
Mackowiak, B., Fu, Y., Maccioni, L., & Gao, B. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176345 · Cited by 359
Taru, V., Szabo, G., Mehal, W., & Reiberger, T. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.016 · Cited by 344
“138 An ongoing RCT is investigating the benefit of treatment with canakinumab, a human monoclonal antibody against IL-1 β in patients with AH (NCT03775109).”
Liver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 310
ACG Clinical Guideline: Alcohol-Associated Liver Disease
Jophlin, L. L., Singal, A. K., Bataller, R., Wong, R. J., Sauer, B. G., Terrault, N. A., & Shah, V. H. (2024) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002572 · Cited by 292
Bataller, R., Arab, J. P., & Shah, V. H. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2207599 · Cited by 259
LeFort, K. R., Rungratanawanich, W., & Song, B.-J. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05061-7 · Cited by 202
Vatsalya, V., Feng, W., Kong, M., Hu, H., Szabo, G., McCullough, A., Dasarathy, S., Nagy, L. E., Radaeva, S., Barton, B., et al. (2023) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002283 · Cited by 64
“Inclusion criteria included the following: age 21years or older, reportedheavydrinking for at least 6 months, and diagnosis of mAH (12#MELD score, 20) and were similar to those published by us for severe AH, except for the lower MELD score indicating mAH (5) (see Supplementary Table 1, SupplementaryDigital Content 1,…”
BackgroundInfluentialSelf-citationInflammation in Alcohol-Associated Hepatitis: Pathogenesis and Therapeutic Targets
Feng, D., Hwang, S., Guillot, A., Wang, Y., Guan, Y., Chen, C., Maccioni, L., & Gao, B. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.04.009 · Cited by 44
Pathogenesis of Alcohol-Associated Liver Disease
Mandrekar, P., & Mandal, A. (2024) · Clinics in Liver Disease · doi:10.1016/j.cld.2024.06.005 · Cited by 34
Design of a multicenter randomized clinical trial for treatment of alcohol-associated hepatitis
Tu, W., Gawrieh, S., Dasarathy, S., Mitchell, M. C., Simonetto, D. A., Patidar, K. R., McClain, C. J., Bataller, R., Szabo, G., Tang, Q., et al. (2023) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2023.101074 · Cited by 21
“The recent DASH trial confirmed that together with pentoxifylline and zinc, anakinra produced survival benefits similar to corticosteroids [17].”
BackgroundResultInfluentialSelf-citation
Metadata
- Authors
- Szabo, G., Mitchell, M., McClain, C. J., Dasarathy, S., Barton, B., McCullough, A. J., Nagy, L. E., Kroll‐Desrosiers, A., Tornai, D., Min, H. A., Radaeva, S., Holbein, M. E. B., Casey, L., & Cuthbert, J.
- Venue
- Hepatology
- Published
- 2022-06-02
- Volume
- 76
- Issue
- 4
- Pages
- 1058-1068
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W4220821037
- Cited by
- 105
- References
- 3
- FWCI
- 13.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.